# A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents

> **NCT00518180** · PHASE3 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 1620 (actual)

## Conditions studied

- Meningococcal Meningitis
- Human Papillomavirus Infection
- Pertussis
- Tetanus

## Interventions

- **BIOLOGICAL:** Novartis Meningococcal ACWY Conjugate Vaccine
- **BIOLOGICAL:** Tdap Vaccine
- **BIOLOGICAL:** Novartis Meningococcal ACWY Conjugate Vaccine

## Key facts

- **NCT ID:** NCT00518180
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2008-04
- **Final completion:** 2008-10
- **Target enrollment:** 1620 (ACTUAL)
- **Last updated:** 2016-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00518180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00518180, "A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00518180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*